Potential Role of Growth Factors With Particular Focus on Growth Hormone and Insulin-Like Growth Factor-1 in the Management of Chronic Kidney Disease

被引:12
作者
Feldt-Rasmussen, Bo [1 ]
El Nahas, Meguid [2 ]
机构
[1] Univ Copenhagen, Rigshosp, Dept Nephrol, Div Nephrol, DK-2100 Copenhagen, Denmark
[2] Univ Sheffield, Sheffield Kidney Inst, Sheffield, S Yorkshire, England
关键词
Chronic kidney disease; growth factors; growth hormone; IGF-1; hemodialysis; dialysis; INTRADIALYTIC PARENTERAL-NUTRITION; MALNOURISHED HEMODIALYSIS-PATIENTS; CHRONIC HEART-FAILURE; QUALITY-OF-LIFE; CARDIOVASCULAR RISK; DIALYSIS PATIENTS; CLINICAL-TRIAL; RENAL-DISEASE; DOUBLE-BLIND; UREMIA;
D O I
10.1016/j.semnephrol.2008.10.007
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Prevention and treatment of chronic kidney disease (CKD) so far primarily has been based on early and aggressive treatment of hypertension. A number of other therapeutic approaches have the potential of being translated to the clinical area within the foreseeable future. In this review, we focus on growth factors and, in particular, on the role of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in the treatment of CKD and the management of its complications. Disturbances of the GH-IGF-1 axis in CKD have suggested therapeutic roles for both the inhibition, as well as the stimulation, of that axis in CKD. Experimental data have suggested that GH may have a detrimental effect on kidney growth, scarring, and the progression of CKD. Therapies based on the inhibition of GH showed some benefit, but failed to translate to clinical CKD. On the other hand, the administration of IGF-1 has been reported in a number of small studies to have conflicting effects on renal function. In end-stage renal disease, GH has been shown in a number of small-scale studies to modify inflammation, improve lipid profile, and favorably affect cardiovascular parameters. Studies also have shown some benefit of IGF-1 administration on the nutritional parameters of patients on renal replacement therapy. More recently, a larger randomized, double-blind, placebo-controlled, 26-week, proof-of-concept clinical study was conducted to investigate the effect of GH (Norditropin; Novo Nordisk, Bagsværd, Denmark) in adult chronic hemodialysis (CHD) patients. Beneficial effects were observed on lean body mass, serum albumin, high-density lipoprotein cholesterol, and homocysteine levels, all known to be associated with mortality and morbidity in CHD. These studies suggested that GH therapy may prove beneficial in reducing morbidity and mortality in CHD patients. © 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:50 / 58
页数:9
相关论文
共 44 条
[1]  
Ansell D, 2006, NEPHROL DIAL TRANSPL, V21, P14
[2]   Treatment targets in renal fibrosis [J].
Boor, Peter ;
Sebekova, Katarina ;
Ostendorf, Tammo ;
Floege, Juergen .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (12) :3391-3407
[3]   Prevalence of kidney damage in Australian adults: The AusDiab Kidney Study [J].
Chadban, SJ ;
Briganti, EM ;
Kerr, PG ;
Dunstan, DW ;
Welborn, TA ;
Zimmet, PZ ;
Atkins, RC .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :S131-S138
[4]   EXPRESSION OF INSULIN-LIKE GROWTH FACTOR-I IN UREMIC RATS - GROWTH-HORMONE RESISTANCE AND NUTRITIONAL INTAKE [J].
CHAN, W ;
VALERIE, KC ;
CHAN, JCM .
KIDNEY INTERNATIONAL, 1993, 43 (04) :790-795
[5]   Effect of growth hormone on cardiac contractility in patients with adult onset growth hormone deficiency [J].
Cho, Goo-Yeong ;
Jeong, In-Kyung ;
Kim, Seong Hwan ;
Kim, Min-Kyu ;
Park, Woo-Jung ;
Oh, Dong-Jin ;
Yoo, Hyung-Joon .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (06) :1035-1039
[6]   Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey [J].
Coresh, J ;
Astor, BC ;
Greene, T ;
Eknoyan, G ;
Levey, AS .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (01) :1-12
[7]   Hormonal adjuvants for the treatment of renal anaemia [J].
Deicher, R ;
Hörl, WH .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2005, 35 :75-84
[8]  
DOI T, 1988, AM J PATHOL, V131, P398
[9]   Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk [J].
Feldt-Rasmussen, Bo ;
Lange, Martin ;
Sulowicz, Wladyslaw ;
Gafter, Uzi ;
Lai, Kar Neng ;
Wiedemann, Jonas ;
Christiansen, Jens Sandal ;
El Nahas, Meguid .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (07) :2161-2171
[10]  
FLYVBJERG A, 2004, PEDIAT ENDOCRINOL S, V3, P525